Management of Hepatitis C Infection with Direct Action Antiviral Drugs (DAA)**

Management of Hepatitis C Infection with Direct Action Antiviral Drugs (DAA)**

<p>Several new direct action antiviral drugs (DAA) against the HCV virus (HCV) are approved and marketed. The combination of DAA with pegylated interferon and ribavirin (PR) is only recommended to patients with tolerance to interferon (IFN). IFN-free treatments are now considered elective drug...

Full description

Saved in:

Bibliographic Details
Main Authors:	Roberto Focaccia (Author), Rodolfo Ferreira de Mello (Author), Patrícia Silva Montes (Author), Flávio Martin Conti (Author)
Format:	Book
Published:	Archives of Hepatitis Research - Peertechz Publications, 2015-12-30.
Subjects:	Review Article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

DAA - directly acting antivirals - as a new, more efficient solution of the chronic hepatitis C treatment and theirs various application.
by: Kamila Abram, et al.
Published: (2023)

P29 Treating hepatitis C virus infection (HCV) with direct acting antivirals (DAAs) through the existing infrastructure of opioid agonist therapy (OAT)
by: J. Keats, et al.
Published: (2017)

Vertical transmission of hepatitis C: towards universal antenatal screening in the era of new direct acting antivirals (DAAs)? Short review and analysis of the situation in Switzerland
by: Karoline Aebi-Popp, et al.
Published: (2016)

Hepatitis C virus infection: Epidemiology in Egypt, Pathophysiology and DAAs-based therapy
by: Heba Elbadawy, et al.
Published: (2021)

P28 Queensland injectors health network (QuIHN) treatment management program (TMP): hepatitis C virus (HCV) direct acting antivirals (DAA) full access for people who inject drugs
by: R. Kavanagh, et al.
Published: (2017)

IP-10 Interferes With the Antiviral Response of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection
by: Yadong Wang, et al.
Published: (2022)

Italian Real-World Analysis of the Impact of Polypharmacy and Aging on the Risk of Multiple Drug–Drug Interactions (DDIs) in HCV Patients Treated with Pangenotypic Direct-Acting Antivirals (pDAA)
by: Fagiuoli S, et al.
Published: (2023)

O11 Hepatitis C: stigma indicators and patient reported outcome measures for DAA treatment
by: C. Treloar, et al.
Published: (2017)

The effect of different direct antivirals on hepatic steatosis in nondiabetic and naïve hepatitis C-infected Egyptian patients
by: Ahmed El-Ghandour, et al.
Published: (2023)

Bioequivalent pharmacokinetics for generic and originator hepatitis C direct-acting antivirals
by: Andrew Hill, et al.
Published: (2018)

Combination of Direct Antiviral Therapy in Hepatitis C Patients, Population of Karachi
by: Samia Perwaiz Khan, et al.
Published: (2020)

On-site testing and case management to improve hepatitis C care in drug users: a prospective, longitudinal, multicenter study in the DAA era
by: Dana Busschots, et al.
Published: (2021)

P38 Hepatitis NSW's specialised counselling service: professional support for people undertaking DAA treatment for viral hepatitis C
by: L. Pesa, et al.
Published: (2017)

Autoimmune hepatitis associated Hepatitis C virus infection treated with fi rst generation direct-acting antivirals
by: Juan Diego Castro Limo, et al.
Published: (2019)

Accessing hepatitis C direct acting antivirals among people living with hepatitis C: a qualitative study
by: Tony Antoniou, et al.
Published: (2023)

Effect of direct-acting antivirals on elastographic measures in patients with chronic hepatitis C virus infection
by: Mohamed M Sakr, et al.
Published: (2019)

Impact of extending direct antiviral agents (DAA) availability in France: an observational cohort study (2015-2019) of data from French administrative healthcare databases (SNDS).
by: Stanislas Pol, et al.
Published: (2022)

Assessment of thyroid function in patients with chronic hepatitis C virus infection before and after treatment with oral direct-antiviral drugs
by: Fathy Ghamry Abdelrazik, et al.
Published: (2021)

Barriers to access to hepatitis C treatment with direct-acting antivirals in people who inject drugs in the community setting
by: Elena Yela, et al.
Published: (2024)

Impact of drug use policy on the appropriate use of direct acting antiviral agents for Hepatitis C in Saudi Arabia
by: Ahmed Saqer Alotaibi, et al.
Published: (2021)

Role of different direct-acting antiviral drugs on hepatitis C virus-associated mixed cryoglobulinemia in Egyptian patients
by: Tarek A Elshazly, et al.
Published: (2019)

Correction: Accessing hepatitis C direct acting antivirals among people living with hepatitis C: a qualitative study
by: Tony Antoniou, et al.
Published: (2023)

Predicting Treatment Failure for Initiators of Hepatitis C Virus Treatment in the era of Direct-Acting Antiviral Therapy
by: Nadia A. Nabulsi, et al.
Published: (2020)

Patients' preferences for treatment with the new direct acting antiviral therapies for chronic hepatitis C virus infection
by: MA Simón, et al.
Published: (2021)

P20 Monitoring the uptake of hepatitis C: direct acting antiviral treatment in Australia
by: B. Hajarizadeh, et al.
Published: (2017)

Adoption of direct-acting antiviral medications for hepatitis C: a retrospective observational study
by: Leah L. Zullig, et al.
Published: (2019)

The effect of cognitive emotion regulation on direct-acting antivirals adherence in patients with hepatitis C
by: Adina Turcu-Stiolica, et al.
Published: (2024)

Strategies for treating and managing chronic hepatitis C in children in the direct-acting antiviral era
by: Suk-Jin Hong, et al.
Published: (2020)

Drug-drug interactions between antithrombotics and direct-acting antivirals in hepatitis C virus (HCV) patients: A brief, updated report
by: Mario Enrico Canonico, et al.
Published: (2022)

The need for a European hepatitis C programme monitoring resistance to direct-acting antiviral agents in real life to eliminate hepatitis C
by: Stephanie Popping, et al.
Published: (2018)

Continuum of hepatitis C care cascade in prison and following release in the direct-acting antivirals era
by: Sanam Hariri, et al.
Published: (2020)

Hepatitis C virus pharmacogenomics in Latin American populations: implications in the era of direct-acting antivirals
by: Trinks J, et al.
Published: (2017)

Retrospective Evaluation on Patient Screening and Counseling Service on Direct-acting Antivirals Against Hepatitis C
by: Bob Ka Him Wong, et al.
Published: (2020)

Direct-acting antivirals for chronic Hepatitis C are effective and safe: an observational study in Londrina/PR
by: Hodnei Takashi Machado, et al.
Published: (2022)

Angiopoietin-2 as a predictor of fibrosis regression in chronic hepatitis C virus patients after direct-acting antiviral drugs
by: Amira Isaac, et al.
Published: (2021)

Efficacy and safety of direct-acting antivirals for treatment of hepatitis C infected kidney transplant recipients; a meta-analysis
by: Wisit Cheungpasitporn, et al.
Published: (2017)

The effect of direct acting antiviral agents on vascular endothelial function in Egyptian patients with chronic hepatitis C virus infection
by: Dalia A Freekh, et al.
Published: (2021)

Impact of direct acting antiviral agents on kidney function in hepatitis C virus infected patients with chronic kidney disease
by: Wedad Adel Mahmoud, et al.
Published: (2021)

Molecular Study of Occult Hepatitis C Infection among Iranian Hemophilia Patients Treated with Direct-acting Antiviral Agents
by: Elnaz Agi, et al.
Published: (2020)

Rate of hepatitis C reinfection after successful direct-acting antivirals treatment among people who inject drugs in Spain: the LIVERate study
by: Fernando Chacón, et al.
Published: (2024)